- Home
- LAZ vs NRIX Comparison
LAZ vs NRIX Comparison
Compare LAZ & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LAZ | NRIX |
|---|---|---|
| Founded | 1848 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 2.8B |
| IPO Year | 2004 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LAZ | NRIX |
|---|---|---|
| Price | $38.30 | $15.15 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 14 |
| Target Price | ★ $43.00 | $33.50 |
| AVG Volume (30 Days) | 1.8M | ★ 3.3M |
| Earning Date | 10-22-2026 | 10-12-2026 |
| Dividend Yield | ★ 5.19% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 1.20 | ★ 3.26 |
| Revenue | ★ $3,186,466,000.00 | $76,987,000.00 |
| Revenue This Year | $6.00 | $786.93 |
| Revenue Next Year | $19.51 | N/A |
| P/E Ratio | $33.88 | ★ $4.89 |
| Revenue Growth | 1.48 | ★ 99.31 |
| 52 Week Low | $34.13 | $12.01 |
| 52 Week High | $58.75 | $28.23 |
Technical Indicators
Market Signals| Indicator | LAZ | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 51.91 | 21.32 |
| Support Level | $34.65 | $14.63 |
| Resistance Level | $45.71 | $17.47 |
| Average True Range (ATR) | 1.67 | 1.29 |
| MACD | 0.25 | -1.25 |
| Stochastic Oscillator | 53.41 | 3.03 |
Price Performance
Historical ComparisonAbout LAZ Lazard Inc.
Lazard Inc is a financial advisory and asset management firm with operations in North and South America, Europe, the Middle East, Asia, and Australia. Lazard provides advice on mergers and acquisitions, capital markets and capital solutions, restructuring and liability management, geopolitics, and other strategic matters, as well as asset management and investment solutions to institutions, corporations, governments, partnerships, family offices, and high net worth individuals. Geographically, the company earns key revenue in the Americas, EMEA then Asia-Pacific.
About NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.